Naloxone attenuates self-abusive behavior in developmentally disabled clients
- PMID: 6870234
- DOI: 10.1016/s0270-3092(83)80014-9
Naloxone attenuates self-abusive behavior in developmentally disabled clients
Abstract
The opiate antagonist naloxone was effective in reducing self-abusive behavior in two mentally retarded clients with an extensive history of such behavior. Three doses of naloxone (0.1, 0.2, 0.4 mg) were compared with a vehicle solution in a double-blind, crossover design. Naloxone greatly attenuated self-abusive episodes in one client and eliminated them entirely in the second client. In addition, use of self-restraining behavior by one client was reduced. The findings suggested that some clients with self-injurious behavior may have disturbances of the endogenous opiate system. Maintenance of self-abuse by tonically elevated pain threshold and/or by the putative addictive characteristics of such behavior was discussed.
Similar articles
-
Failure of naloxone to reduce self-injurious behavior in two developmentally disabled females.Appl Res Ment Retard. 1986;7(2):183-8. doi: 10.1016/0270-3092(86)90004-4. Appl Res Ment Retard. 1986. PMID: 3729382 Clinical Trial.
-
Effects of naloxone on self-injurious behavior: a case study.Appl Res Ment Retard. 1983;4(1):1-4. doi: 10.1016/s0270-3092(83)80013-7. Appl Res Ment Retard. 1983. PMID: 6307142
-
Naltrexone in treatment of self injurious behavior: a clinical study.Res Dev Disabil. 1987;8(2):179-90. doi: 10.1016/0891-4222(87)90002-3. Res Dev Disabil. 1987. PMID: 3671810
-
Pharmacological treatment of self-injurious behavior in mentally retarded persons.J Autism Dev Disord. 1985 Sep;15(3):257-67. doi: 10.1007/BF01531497. J Autism Dev Disord. 1985. PMID: 2863252 Review.
-
Self-injurious behavior: a review of the behavior and biology of self-mutilation.Am J Psychiatry. 1991 Mar;148(3):306-17. doi: 10.1176/ajp.148.3.306. Am J Psychiatry. 1991. PMID: 1847025 Review.
Cited by
-
Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities.Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD009084. doi: 10.1002/14651858.CD009084.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633366 Free PMC article.
-
Brain opioids and autism: an updated analysis of possible linkages.J Autism Dev Disord. 1987 Jun;17(2):201-16. doi: 10.1007/BF01495056. J Autism Dev Disord. 1987. PMID: 3038836
-
A case report of naltrexone treatment of self-injury and social withdrawal in autism.J Autism Dev Disord. 1990 Jun;20(2):169-76. doi: 10.1007/BF02284716. J Autism Dev Disord. 1990. PMID: 2189867 Clinical Trial.
-
Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children.J Autism Dev Disord. 1991 Jun;21(2):243-9. doi: 10.1007/BF02284764. J Autism Dev Disord. 1991. PMID: 1864831 No abstract available.
-
Brief report: plasma beta-endorphin and cortisol levels in autistic patients.J Autism Dev Disord. 1991 Mar;21(1):83-7. doi: 10.1007/BF02207000. J Autism Dev Disord. 1991. PMID: 2037552 No abstract available.